Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Amortizatization of Intangibles (2019 - 2025)

BioNexus Gene Lab's Amortizatization of Intangibles history spans 7 years, with the latest figure at $14354.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 3.06% year-over-year to $14354.0; the TTM value through Sep 2025 reached $55142.0, up 22.38%, while the annual FY2024 figure was $48983.0, 94.61% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $14354.0 at BioNexus Gene Lab, up from $13933.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $14807.0 in Q3 2024 and bottomed at $1238.0 in Q4 2022.
  • The 5-year median for Amortizatization of Intangibles is $4434.0 (2021), against an average of $7723.4.
  • The largest annual shift saw Amortizatization of Intangibles tumbled 66.74% in 2022 before it skyrocketed 671.41% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $3722.0 in 2021, then tumbled by 66.74% to $1238.0 in 2022, then surged by 671.41% to $9550.0 in 2023, then soared by 41.11% to $13476.0 in 2024, then rose by 6.52% to $14354.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Amortizatization of Intangibles are $14354.0 (Q3 2025), $13933.0 (Q2 2025), and $13379.0 (Q1 2025).